Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00366652
NCT00366652
Completed
Phase 3

A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 sites20 target enrollmentSeptember 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDepressionDepressive DisorderDepressive Disorder, Major
Drugsdesvenlafaxine SRdesipramineduloxetine

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Depression
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
20
Primary Endpoint
The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.

Registry
clinicaltrials.gov
Start Date
September 2006
End Date
September 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The primary outcome of the study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.

Similar Trials

Completed
Phase 3
Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy SubjectsDepression
NCT00329147Wyeth is now a wholly owned subsidiary of Pfizer20
Completed
Phase 4
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of MidazolamMajor Depressive Disorder
NCT00952653Pfizer28
Completed
Phase 1
Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)Mood DisorderSubstance-Related DisordersAmphetamine-Related Disorders
NCT00990067University Hospital, Basel, Switzerland16
Completed
Phase 3
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive DisorderDepressive Disorder, Major
NCT00300378Wyeth is now a wholly owned subsidiary of Pfizer480
Completed
Phase 3
Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal WomenMenopauseVasomotor System
NCT00369434Wyeth is now a wholly owned subsidiary of Pfizer450